UroGen Pharma FY2024 EPS Estimate Lifted by HC Wainwright

UroGen Pharma Ltd. (NASDAQ:URGN) – Equities researchers at HC Wainwright increased their FY2024 EPS estimates for UroGen Pharma in a report issued on Thursday, November 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($3.01) per share for the year, up from their prior estimate of ($3.41). HC Wainwright currently has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q4 2024 earnings at ($0.65) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.70) EPS and FY2025 earnings at ($3.06) EPS.

Other analysts have also recently issued research reports about the stock. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, Guggenheim began coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $48.38.

UroGen Pharma Price Performance

URGN opened at $12.12 on Monday. The company has a debt-to-equity ratio of 4.77, a quick ratio of 7.93 and a current ratio of 9.00. The stock has a market capitalization of $284.21 million, a PE ratio of -3.85 and a beta of 1.12. The stock’s 50 day moving average price is $12.75 and its 200-day moving average price is $14.17. UroGen Pharma has a 52-week low of $10.60 and a 52-week high of $20.70.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million for the quarter, compared to the consensus estimate of $24.22 million. During the same period in the previous year, the company earned ($0.68) EPS.

Hedge Funds Weigh In On UroGen Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in URGN. Intech Investment Management LLC bought a new position in shares of UroGen Pharma in the 3rd quarter worth about $155,000. GSA Capital Partners LLP purchased a new stake in UroGen Pharma in the third quarter worth about $249,000. Rice Hall James & Associates LLC increased its stake in shares of UroGen Pharma by 273.6% during the third quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company’s stock valued at $3,453,000 after purchasing an additional 199,110 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after purchasing an additional 3,856 shares during the last quarter. Finally, Wesbanco Bank Inc. bought a new stake in shares of UroGen Pharma in the 3rd quarter worth approximately $945,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.